Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leiomyoma 1

Interventions

anlotinib 5Cisplatin 5Carboplatin 5Immune Checkpoint Inhibitors 4tislelizumab 3sintilimab 3lenvatinib 3Oxaliplatin 3Fluorouracil 3Capecitabine 3Bevacizumab 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Gemcitabine 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1toripalimab 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × DMAC2L protein, human × Clear all
NCT06640738 2024-10-15

Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation

Kaohsiung Medical University

Phase 4 Not yet recruiting
60 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡